While cerebrospinal fluid (CSF) neurogranin levels correlate with tau proteins and cognitive decline, indicating synaptic loss [17], plasma SNAP-25 levels are elevated in AD patients and correlate with cognitive function and cortical atrophy [18], suggesting their potential as blood-based biomarkers for synaptic damage in AD. This evidence concerns the gene MAPT and Alzheimer disease.